
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is expected to reach profitability without equity raises due to their transformative strategy pivot to incorporate a core royalty aggregation model, allowing for compounding of revenue-generating royalties and the retention of in-house R&D capabilities which reduces binary risk. With their strong team and a promising clinical pipeline, Zymeworks is well positioned for success in the future and is a Buy-rated stock with a 12-month price target of $58.
Bears say
Zymeworks is currently trading at a high valuation, despite its narrow pipeline and limited sales compared to its competitors in the biopharmaceutical industry. The company's investing strategy of focusing on preclinical/earlier-stage data-driven differentiation and a lack of commercial-stage assets may also make it vulnerable to clinical trial failures or difficulties in obtaining regulatory approval and commercial success. Additionally, the company's reliance on partnerships for funding and market share in its targeted areas may lead to greater uncertainty and financial risk for investors.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares